If you're feeling good about the market, you're not alone. Take my hand as we go over some of this week's more uplifting headlines.

1. Amazon streams on
One of Amazon.com's (Nasdaq: AMZN) worst-kept secrets is finally official. The leading online retailer announced that it would be offering streaming on select content at no additional cost to customers already paying $79 a year for subsidized shipping through Amazon Prime.

Amazon's selection of available freebies may be limited to just 5,000 movies and television shows, but it's the best way to scale quickly in order to compete against Netflix (Nasdaq: NFLX).

Amazon claims that it already has millions of Prime members, and it's a safe bet that many of them have never ordered premium digital rentals and purchases through Amazon Instant Video. Amazon will have some legwork to do in getting its streams into the video game consoles, smartphones, and tablets as Netflix has done, but this should be a sticky offering that will increase a la carte digital video purchases. Attracting movie buffs to Prime memberships should also help increase overall sales.  

2. The NetEase professor
NetEase.com
(Nasdaq: NTES) is still playing to win. The Chinese online gaming giant posted another blowout quarter on Wednesday. Revenue climbed 31%, fueled by a 31% gain in its flagship gaming business and a healthy 27% uptick at its popular online portal. Even its mobile messaging business, which was once seemingly left for dead, showed signs of life.

Earnings climbed a better-than-expected 25%. The bottom-line showing would've kept up with the top-line spurt if NetEase didn't have to account for a currency hit for parking most of its $1.2 billion in time deposits in euro-denominated banks.

Nobody's perfect, but if the biggest knock on you is that you have too much money collecting interest in the wrong bank you know you're doing things right.

3. Love is the drug
A good way to buck this week's general malaise was to bet on biotechs putting out positive pipeline news.

Shares of Exelixis (Nasdaq: EXEL) and Vertex Pharmaceuticals (Nasdaq: VRTX) gained ground on upbeat clinical trial news.

Later this year, Exelixis will begin testing its prostate cancer drug cabozantinib as a possible treatment for other types of cancer. Vertex's VX-770 received positive data from a drug trial, showing improved lung function in some patients with cystic fibrosis.

Patience will be required to see either of these catalysts fully play out, but the welcome news from both camps was enough to deliver healthy pops on otherwise dreary trading days.

4. This is what brown can do for you
The surge in oil prices is bad news for more than just you at the gas pump. Higher prices will increase food costs, pinch airline margins, and even sting homebuilders looking to fill vacant homes out in the suburbs. However, there will be a few beneficiaries.

Clean Energy Fuels (Nasdaq: CLNE) is one of the winners. Clean Energy Fuels is building out a network of natural gas fueling stations. It already has commitments from Los Angeles and Atlantic City for its bus-fueling stations. This week, it landed a contract with UPS to fuel up its new fleet of 48 liquefied natural gas trucks.

5. Drove my Chevy to the levy
General Motors
(NYSE: GM) may have missed Wall Street's profit expectations in its latest quarter, but the real takeaway here is that the automaker just delivered its first annual profit since 2004.

Mr. Market doesn't see it that way. The stock hit a new post-IPO low yesterday. However, this is ultimately validation of the bankruptcy reorganization process that created a leaner debt structure to transform GM into the profitable automaker that it is now today.

The spike in oil prices may also be hurting, but I don't necessarily see that as a roadblock. Higher prices at the pump may actually encourage drivers to trade their gas hogs for the more fuel-efficient cars rolling off the assembly lines these days.

Don't let us down, Chevy Volt!

General Motors is a Motley Fool Inside Value recommendation. Exelixis, NetEase.com, and Vertex Pharmaceuticals are Motley Fool Rule Breakers selections. Amazon.com and Netflix are Motley Fool Stock Advisor picks. The Fool owns shares of Exelixis and United Parcel Service. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Longtime Fool contributor Rick Munarriz is an optimist at every turn. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.